BAXTER INTL INC shareholders Q3 2023

BAXTER INTL INC's ticker is BAX and the CUSIP is 071813109. A total of 885 filers reported holding BAXTER INTL INC in Q3 2023. The put-call ratio across all filers is 0.40 and the average weighting 0.2%.

BAXTER INTL INC shareholders Q3 2023
NameSharesValueWeighting ↓
MEYER HANDELMAN CO 232,088$8,759,0010.35%
BOOTHBAY FUND MANAGEMENT, LLC 386,856$14,599,9450.35%
Brandywine Global Investment Management, LLC 1,028,962$38,833,0260.34%
Westchester Capital Management, LLC 304,800$11,503,1520.34%
AXQ CAPITAL, LP 24,800$935,9520.33%
Quantum Private Wealth, LLC 17,184$648,5250.31%
Aspen Grove Capital, LLC 21,803$831,5650.31%
Triangle Securities Wealth Management 22,415$845,9420.30%
LIBERTY ONE INVESTMENT MANAGEMENT, LLC 55,107$2,079,7290.30%
Lipe & Dalton 13,180$4970.30%
Savoie Capital LLC 30,000$1,132,2000.30%
Cito Capital Group, LLC 15,550$5910.29%
Murphy Pohlad Asset Management LLC 17,276$652,0020.29%
South Dakota Investment Council 326,435$12,3200.28%
SHERBROOKE PARK ADVISERS LLC 22,582$852,2450.27%
Columbia Trust Co 01012016 12,206$460,6540.27%
Cubic Asset Management, LLC 25,199$951,0100.26%
Gifford Fong Associates 29,000$1,0940.26%
WHITENER CAPITAL MANAGEMENT, INC. 17,349$654,7510.26%
STATE FARM MUTUAL AUTOMOBILE INSURANCE CO 6,853,390$258,646,9390.26%
About BAXTER INTL INC

Baxter International Inc. is a global healthcare company that specializes in developing and manufacturing medical products and therapies. The company has a long history of innovation and has been at the forefront of developing life-saving treatments for patients around the world.

Baxter's product portfolio includes a wide range of medical devices, pharmaceuticals, and biotechnology products. The company's products are used in hospitals, clinics, and other healthcare settings to treat a variety of conditions, including hemophilia, immune disorders, kidney disease, and other chronic and acute medical conditions.

Baxter's commitment to innovation has helped the company maintain a strong position in the healthcare industry. The company invests heavily in research and development, and has a strong pipeline of new products in development.

Baxter's leadership team is also a key strength of the company. The CEO, José Almeida, has a strong track record of success in the healthcare industry, and has been instrumental in driving the company's growth and success.

Overall, Baxter International Inc. is a strong and innovative company that is well-positioned to continue delivering value to patients, healthcare providers, and investors alike. With a strong product portfolio, a commitment to innovation, and a talented leadership team, Baxter is a company that investors should keep an eye on in the years to come.

It's important to note that this information is for educational purposes only and has not been fact-checked. As with any investment, it's important to do your own research and consult with a financial advisor before making any investment decisions.

External links

This page lists BAXTER INTL INC's shareholders in Q3 2023. To view BAXTER INTL INC's shareholder history, click here.